Clinical trials
Observational Down Syndrome trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
72 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2008 | 3 |
| 2009 | 8 |
| 2010 | 2 |
| 2011 | 4 |
| 2012 | 8 |
| 2013 | 6 |
| 2014 | 6 |
| 2015 | 5 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 5 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 44 |
| Recruiting | 13 |
| Terminated | 9 |
| Unknown status | 6 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Natera, Inc. | 8 |
| Sequenom, Inc. | 8 |
| University of Colorado, Denver | 5 |
| Children's Hospital Medical Center, Cincinnati | 3 |
| Hoffmann-La Roche | 3 |
| Progenity, Inc. | 3 |
| Women and Infants Hospital of Rhode Island | 3 |
| Children's Healthcare of Atlanta | 2 |
| Duke University | 2 |
| LuMind IDSC Foundation | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Down Syndrome | 72 |
| Trisomy 18 Syndrome | 21 |
| Trisomy 13 Syndrome | 18 |
| Turner Syndrome | 12 |
| Aneuploidy | 11 |
| Alzheimer Disease | 10 |
| Sex Chromosome Aberrations | 7 |
| DiGeorge Syndrome | 5 |
| Trisomy | 5 |
| Klinefelter Syndrome | 4 |
Trials
Showing 1 to 25 of 72. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.